Tetracaine
Kovanaze, Pliaglis (tetracaine) is a small molecule pharmaceutical. Tetracaine was first approved as Synera on 2005-06-23. It is used to treat pain in the USA.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Combinations
Kovanaze, Pliaglis (discontinued: Synera)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| cetacaine anesthetic | unapproved drug other | 2023-05-11 |
| kovanaze | New Drug Application | 2018-11-16 |
| pliaglis | New Drug Application | 2021-01-12 |
| synera | New Drug Application | 2020-12-22 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pain | EFO_0003843 | D010146 | R52 |
Agency Specific
FDA
EMA
No data
ATC Codes
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05A: Agents for treatment of hemorrhoids and anal fissures for topical use
— C05AD: Local anesthetics for treatment of hemorrhoids and anal fissures for topical use
— C05AD02: Tetracaine
D: Dermatologicals
— D04: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04A: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04AB: Anesthetics for topical use
— D04AB06: Tetracaine
N: Nervous system drugs
— N01: Anesthetics
— N01B: Local anesthetics
— N01BA: Esters of aminobenzoic acid for local anesthesia
— N01BA03: Tetracaine
— N01BA53: Tetracaine, combinations
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01H: Local anesthetics, ophthalmologic
— S01HA: Local anesthetics
— S01HA03: Tetracaine
HCPCS
Code | Description |
|---|---|
| C9285 | Lidocaine 70 mg/tetracaine 70 mg, per patch |
Clinical
Clinical Trials
3 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tetanus | D013742 | EFO_0005593 | A35 | 1 | 1 | 1 | 1 | — | 3 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TETRACAINE |
| INN | tetracaine |
| Description | Tetracaine is a benzoate ester in which 4-N-butylbenzoic acid and 2-(dimethylamino)ethanol have combined to form the ester bond; a local ester anaesthetic (ester caine) used for surface and spinal anaesthesia. It has a role as a local anaesthetic. It is a benzoate ester and a tertiary amino compound. |
| Classification | Small molecule |
| Drug class | local anesthetics |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCNc1ccc(C(=O)OCCN(C)C)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 94-24-6 |
| RxCUI | 10391 |
| ChEMBL ID | CHEMBL698 |
| ChEBI ID | 9468 |
| PubChem CID | 5411 |
| DrugBank | DB09085 |
| UNII ID | 0619F35CGV (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,922 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
45 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more